Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders ...

McEwen Inc. ( MUX) Q3 2025 Earnings Call November 6, 2025 11:00 AM EST ...

Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...

Nearly two-thirds of coastal regions saw intensifying 50-year wind speeds, putting sector development particularly in Asia ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

Viridian Therapeutics, Inc. nears profitability and gears up for veligrotug’s 2025 launch. Click here to find out why VRDN ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's deadliest infectious disease.

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study – Cash burn of $4.2 million in Q3 remains in line with ...

HealthDay News — Two human leukocyte antigen (HLA) class I alleles are independently associated with an increased risk for allopurinol-induced severe cutaneous adverse reactions (SCARs), according to ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine ...

Tactical Adventures gives a more accurate Solasta 2 release date window, along with the details on which classes will be ...